Get startedLog in
    Picture of SpringWorks Therapeutics logo

    SWTX — SpringWorks Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapNeutral
    All News

    Brief: Springworks Therapeutics Completes Enrollment Of Mid-stage Study For Ovarian Tumor Drug

    Picture of SpringWorks Therapeutics logoSpringWorks Therapeutics
    30/05/2023 11:33
    May 30 (Reuters) - SpringWorks Therapeutics Inc
 SWTX.O :
    * SPRINGWORKS THERAPEUTICS ANNOUNCES FULL ENROLLMENT OF
PHASE 2
TRIAL EVALUATING NIROGACESTAT IN PATIENTS WITH OVARIAN GRANULOSA
CELL TUMORS

Source text for Eikon:  ID:nGNXc8yzqb 
Further company coverage:  SWTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on SpringWorks Therapeutics

    See all news